Reuters

The amount of money big U.S. pharmaceutical manufacturers have paid to settle charges for violating federal health care laws has declined sharply in recent years, prompting a non-profit watchdog group to call for an increase in enforcement efforts.<div class="paywall-selector"></div><div class="paywall">
In a new analysis that chronicles 25 years worth of pharmaceutical industry settlements and court judgments, the group, known as Public Citizen, found that just $2.4 billion in federal financial penalties were recovered from 2014 to 2015 — a figure that is less than one third of the $8.7 billion recovered from 2012 to 2013.
The report calls for larger penalties and possible prison sentences, noting that without tougher sanctions, illegal activities will continue to be &#8220;part of the companies&#8217; business model.&#8221;
The report also found there was a nearly 80 percent drop in settlements between companies and states in 2014-2015 from 2012-2013.
In addition, the report found that in 2014-2015, criminal penalties against large pharmaceutical companies have reached new lows, totaling only $44 million, compared to $2.7 billion from 2012 to 2013.
Sammy Almashat, one of the researchers at Public Citizen who helped author the report, said the cause for the decline in settlements is still not clear.
The report explores several possible reasons, from a drop in enforcement and shifts away from off-label marketing prosecutions, to changes in Medicaid pharmaceutical reimbursement strategies.
But Almashat said he does not believe the decrease reflects improvement by large pharmaceutical companies in their overall corporate compliance.
&#8220;Previous penalties never have been large enough to deter the most common types of pharmaceutical fraud,&#8221; he said in a statement. &#8220;So it would be surprising if the industry suddenly decided of its own accord to comply with laws it has routinely violated for decades.&#8221;
Thursday&#8217;s report updates a prior study that Public Citizen released in 2012 that explores federal and state enforcement in the sector dating back to 1991.
Over the 25-year study period, Public Citizen found that GlaxoSmithKline (GSK) and Pfizer (PFE) have paid the most in financial penalties, with GlaxoSmithKline paying $7.9 billion and Pfizer paying $3.9 billion.
The report also for the first time provides a list of &#8220;repeat offenders&#8221; that have repeatedly broken a variety of federal health care laws over the years.
Pfizer tops the list with the most settlements, followed by Merck (MRK). GlaxoSmithKline, Novartis (NVS) and Bristol-Myers Squibb (BMY) tied for third place.
Spokespeople for Bristol-Myers, Merck and Novartis declined to comment, and the others did not have an immediate comment.</div>

Fines big U.S. pharma has paid for violating federal laws has declined recently, prompting a watchdog group to call for more enforcement.

U.S. Big Pharma Isn't Paying Enough Fines for Breaking the Law

Drugs From European Pharmaceuticals Companies As Stocks Outperformed The Stoxx 600 Index By 1.2 percentage Points

legacy

Health

Leadership

Watchdog Says U.S. Big Pharma Isn’t Paying Enough for Breaking the Law

U.S. Big Pharma Isn't Paying Enough Fines for Breaking the Law | Fortune

Alexa Mikhail

5 ways to reduce your dementia risk as study estimates U.S. cases could double by 2060

/well/article/dementia-risk-lifestyle-prevention/

The Associated Press

Hallie Steiner

A pile of candy hearts with messages written on them for Valentine's Day

What foods have Red dye 3? Candy Corn, red icing, and other favorite snacks

/well/2025/01/16/what-foods-have-red-dye-3-candy-corn-icing-snacks-red-40-hyperactivity-cancer/

Lindsey Leake

As part of its quest to “discover the science of humanity,” the Truveta Genome Project will gather the de-identified genetic data of tens of millions of consented volunteers, health data startup Truveta announced Jan. 13, 2025.

Pharma giant Regeneron is spending $119.5M on the world’s largest, most diverse genetic database using DNA from patient volunteers

/well/article/truveta-genome-project-regeneron-illumina/

Ani Freedman

Tea bags and these 11 foods are likely exposing you to billions of microplastics

/well/article/tea-bags-microplastics-endocrine-disruptors-nanoplastics-health-risks/

Beth Greenfield

Woman in hospital bed with head wrap, suggesting cancer

Cancer deaths are down, but rates in women under 50 are rising

/well/2025/01/16/cancer-rates-in-women-under-50-rising/

FDA bans red dye No. 3 from foods, supplements, and some medicines because of potential cancer risk

/well/2025/01/15/fda-bans-red-dye-no-3-from-foods/

Christiaan Hetzner

UnitedHealth, employer of slain exec Brian Thompson, found to have overcharged some cancer patients for drugs by over 1,000%

https://fortune.com/2025/01/15/ftc-pbms-unitedhealth-brian-thompson-cvs-caremark-cigna-pharmacy-benefit-managers/?itm_source=parsely-api

Tiffani Potesta

Gen Xers expect to keep working longer than they planned–and will be the first generation to go into retirement with less financial security than their parents and grandparents

https://fortune.com/article/how-much-does-gen-x-have-saved-retirement-savings-average-age-account-crisis/?itm_source=parsely-api

Marco Quiroz-Gutierrez

TikTok's CEO used to work for Mark Zuckerberg as a Facebook intern. Just one decade later, he's become one of Meta's fiercest competitors

https://fortune.com/2025/01/15/tiktok-ceo-shou-zi-chew-mark-zuckerberg-intern-facebook/?itm_source=parsely-api

Beatrice Nolan

Elon Musk bet me $1 million the U.S. would not see 35,000 cases of Covid—then turned on me when it happened, says Sam Harris

https://fortune.com/2025/01/16/elon-musk-bet-covid-cases-sam-harris/?itm_source=parsely-api

Eleanor Pringle

Jamie Dimon's 'hit by a bus' successor Daniel Pinto leaves JPMorgan—and the new COO says she doesn't want the top job either

https://fortune.com/2025/01/15/jamie-dimon-succession-pinto-piepszak-jp-morgan-ceo-planning/?itm_source=parsely-api

Fortune Editors

The CEO of Crunch Fitness doesn’t think there’s such a thing as work-life balance: 'That’s for somebody who's not fully committed'

https://fortune.com/article/what-is-work-life-balance-ceo-crunch-fitness-healthy-maintain-best-benefits/?itm_source=parsely-api